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A major limitation in the identification of novel antichlamydial compounds is the paucity of effective methods for large-scale
compound screening. The immunofluorescence assay is the preferred approach for accurate quantification of the intracellular
growth of Chlamydia. In this study, an immunofluorescence image-based method (termed image-based automated chlamydial
identification and enumeration [iBAChIE]) was customized for fully automated quantification of Chlamydia infection using the
freely available open-source image analysis software program CellProfiler and the complementary data exploration software
program CellProfiler Analyst. The method yielded enumeration of different species and strains of Chlamydia highly comparably
to the conventional manual methods while drastically reducing the analysis time. The inhibitory capability of established anti-
chlamydial activity was also evaluated. Overall, these data support that iBAChIE is a highly effective tool for automated quantifi-
cation of Chlamydia infection and assessment of antichlamydial activities of molecules. Furthermore, iBAChIE is expected to be
amenable to high-throughput screening studies for inhibitory compounds and fluorescently labeled molecules to study host-
pathogen interactions.
Chlamydia trachomatis is the leading cause of bacterial sexuallytransmitted infection (STI) in the United States, for which
novel preventative and therapeutic compounds are needed (3).
The vast majority (up to 75%) of C. trachomatis infections in
women are asymptomatic (19), and if left untreated, these infec-
tions can lead to serious complications, including pelvic inflam-
matory disease (PID), ectopic pregnancy, and infertility (5, 6, 15).
Moreover, genital C. trachomatis infection has been shown to as-
sociate with cervical cancer development and to contribute signif-
icantly to HIV transmission (8, 22). While current antibiotics are
effective, resistance to the clinically preferred antibiotic (i.e.,
doxycycline) has already been observed in a Chlamydia species,
albeit a nonhuman isolate (C. suis) (13; A. A. Andersen and D. G.
Rogers, presented at the 9th International Symposium on Human
Chlamydial Infection, International Chlamydia Symposium, San
Francisco, CA, 1998). Prevention strategies are essential given the
high rate of asymptomatic C. trachomatis infections; however, a
vaccine or vaginal microbicide effective in preventing Chlamydia
infection is currently unavailable for clinical use.
A major limitation in the development of antichlamydial com-
pounds is the lack of a well-established method for quantifying
Chlamydia infection that is adaptable to a high-throughput
screening format. The paucity of high-throughput screening
methods is heavily influenced by the obligate intracellular growth
characteristics and the inability for axenic cultivation of Chla-
mydia. As a result, the direct immunofluorescent assay (IFA) is
predominately relied on for accurate detection of Chlamydia in-
fection. The established procedure depends on visual inspection
of the intracellular vacuole formed by Chlamydia, termed an in-
clusion, typically within a relatively low number of fields (e.g., 3 to
10). The limitations of manual enumeration are evident; the pro-
cess is labor intensive, field selection is prone to subjectivity, and
results are based on a relatively restricted data set.
Freely available open-source computational image analysis
software, CellProfiler (http://www.cellprofiler.org), has been
shown to be an effective tool for quantifying visual information in
a variety of biological images, particularly in large-scale imaging
experiments (2). The complement software, CellProfiler Analyst,
performs analysis of image-derived quantitative information as
defined within a very large collection of image-feature measure-
ments (i.e., a cytological profile) produced by CellProfiler. Cell-
Profiler Analyst contains a supervised machine-learning system
that is intuitive for development of image analysis algorithms via
visual perception using a user-friendly interface (9, 10).
In this study, image-based automated chlamydial identifica-
tion and enumeration (iBAChIE) was developed using CellPro-
filer and CellProfiler Analyst. To validate iBAChIE, the commonly
utilized laboratory strain (LGV-2) and the more clinically relevant
strain (serovar D) of C. trachomatis were analyzed. The accuracy
and expediency of the automated method were compared to those
of the conventional visual inspection in a 96-well format. For eval-
uating the efficacy and potential of iBAChIE to measure antichla-
mydial compounds, C. trachomatis infections were measured
following treatment with four anti-Chlamydia molecules (tetracy-
cline, polymyxin B, hydroxyethyl cellulose, and anti-C. trachoma-
tis polyclonal antibody) that have contrasting mechanisms of in-
hibitory activity toward C. trachomatis (4, 7, 11, 12, 20, 23, 26).
MATERIALS AND METHODS
Bacteria and cell culture. C. trachomatis lymphogranuloma venereum
(LGV) serovar L2/434/Bu elementary bodies (EBs) were purified from
infected L929 cells using a 30% Renografin density gradient (21) and
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stored in sucrose phosphate glutamate (SPG) at 80°C until use. C. tra-
chomatis serovar D/UW-3/Cx was isolated from infected HeLa 229 cells
and C. muridarum strain Nigg was purified from infected L929 cells as
described previously (21). L929 cells and HeLa 229 cells were routinely
cultured in RPMI 1640 tissue culture medium (Mediatech, Inc., Manas-
sas, VA) supplemented with 5% fetal bovine serum (FBS) (Thermo Fisher
Scientific, Liverpool, NY) and 10 g/ml gentamicin (MP Biomedicals,
Santa Ana, CA) at 37°C in a humidified atmosphere of 5% CO2. Cells were
seeded in 96-well plates (Bioexpress, Kaysville, UT) at a density of 7  104
cells/ml, 200 l/well, and incubated overnight prior to infection. In order
to minimize the edge effect (well-to-well variations in the number of
cells), plated cells were incubated for 1 h at room temperature prior to
incubation at 37°C in an atmosphere of 5% CO2, as previously described
(14).
Microbicide and antibiotic preparation. Polymyxin B sulfate (Enzo
Life Science, New York, NY) and tetracycline hydrochloride (USB Corpo-
ration, Cleveland, OH) were obtained in powder form. Stock solution of
polymyxin B sulfate was prepared in Hanks buffered salt solution (HBSS)
(Mediatech, Inc., Holly Hill, FL) to a concentration of 10 mM. Tetracy-
cline was dissolved in sterile water to a stock concentration of 1 mg/ml.
Hydroxyethyl cellulose (HEC) (90 kDa; Sigma-Aldrich, St. Louis, MO)
was prepared as a stock solution at a concentration of 12% (wt/vol) in
water. The HEC gel (polymeric liquid) was adjusted to pH 4.5 using 10 M
NaOH and stored at 4°C. At the time of the assay, a 12% HEC gel was
diluted to a final concentration of 2.8% (wt/vol) in phosphate-buffered
saline (PBS). The mixture was shaken for 1 h at 37°C to achieve a uniform
solution, centrifuged for 1 min at 300  g to remove any bubbles, adjusted
to pH 7.0, and stored at 4°C until use.
EB dilution assay. Purified C. trachomatis L2 EBs were serially diluted
2-fold in HBSS and transferred to 70% confluent L929 cell monolayers
(90 l/well) in a 96-well plate. Ninety microliters of HBSS alone was
added to mock-infected control cells. Cells were incubated for 2 h at room
temperature. Following the incubation period, chlamydial inocula were
removed and cells were washed once with 200 l of HBSS. Two hundred
microliters of fresh medium (RPMI–5% fetal bovine serum–10 g per ml
gentamicin) was added to each well, and cells were incubated at 37°C in an
atmosphere of 5% CO2 for 24 h.
Antichlamydial compound inhibitory assay. C. trachomatis L2 EBs
were diluted in HBSS. Polymyxin B and hydroxyethyl cellulose were seri-
ally diluted 2-fold in HBSS containing EBs to the concentration range of 1
mM to 15.625 M and 2.8% to 0.175%, respectively. Compound-EB mix-
tures were incubated for 60 min at room temperature. Compound-
treated EB inocula were mixed using a multichannel pipette (LabNet Ex-
cel, Edison, NJ) at the start and end of the incubation period to ensure
uniformity of the inocula. The mixtures containing the compound and
EBs were then transferred to 70% confluent L929 cell monolayers in a
96-well plate and incubated at room temperature for 2 h. Following the
incubation period, the inocula were removed and cells were washed once
with 200 l of HBSS. Two hundred microliters of fresh medium
(RPMI–5% fetal bovine serum–10 g per ml gentamicin) was added to
each well. For tetracycline treatment, fresh medium containing an appro-
priate concentration (0.1 to 0.7 g/ml) of tetracycline was added follow-
ing 2-h inoculation period. Cells were incubated at 37°C in an atmosphere
of 5% CO2 for 24 h.
C. trachomatis serovar D and C. muridarum infection. Purified C.
trachomatis serovar D or C. muridarum was serially diluted 4-fold in HBSS
and transferred to 70% confluent HeLa 229 or L929 cell monolayers (90
l/well) in a 96-well plate, respectively. Ninety l of HBSS alone was
added to mock-infected control cells. The plate was centrifuged at 900  g for
1 h at room temperature (21). Following the incubation period, chlamyd-
ial inocula were removed and cells were washed once with 200 l of HBSS.
Two hundred microliters of fresh medium (RPMI–5% fetal bovine se-
rum–10 g per ml gentamicin) was added to each well, and cells were
incubated at 37°C in an atmosphere of 5% CO2 for 48 h for serovar D and
for 24 h for C. muridarum before they were analyzed.
Neutralization assay. Guinea pig polyclonal serum against Chlamydia
L2 EBs was purchased from Abcam (Cambridge, MA). Rabbit polyclonal
anti-RpoA antibody was affinity purified using the AminoLink Plus im-
mobilization kit (Thermo Scientific, Rockford, IL). The protein concen-
tration of purified antibody was determined to be 1.01 mg/ml by Bradford
assay (Bio-Rad Laboratories, Hercules, CA). Sera and purified antibody
were serially diluted 5-fold in HBSS. Prior to infection, purified C. tracho-
matis L2 EBs were added to each serum or purified antibody sample and
incubated for 30 min at 37°C to allow interaction between EBs and the
antibody to take place (24). HBSS alone was used as a negative control.
Following the incubation period, 90 l of each sample containing anti-
body-EB mixture was added to a monolayer of L929 cells in a 96-well plate
and incubated at room temperature for 2 h. After the incubation period,
inocula were removed and cells were washed once with HBSS. Two hun-
dred microliters of fresh medium (RPMI–5% fetal bovine serum–10 g
per ml gentamicin) was added to each well, and cells were incubated at
37°C for 24 h.
Immunofluorescence assay (IFA). At 24 or 48 h postinfection (hpi)
for serovar L2 or D, respectively, infected cells were fixed with 100%
methanol (200 l/well) for 10 min at room temperature and washed once
with PBS. Cells were stained using the MicroTrack C. trachomatis culture
confirmation test (Syva Co., Palo Alto, CA) with dilution to 1:40 in PBS
(50 l/well) for 60 min in the dark, followed by a 5-min staining with 1
M 4=,6-diamidino-2-phenylindole (DAPI) in PBS (50 l/well). DAPI
was removed, and 1 ml of PBS was added. Plates were stored in the dark at
4°C until imaging.
Image acquisition. Images were automatically captured with a BD
Pathway BioImager 855 microscope (Becton, Dickinson and Company,
Franklin Lakes, NJ) with a 20, 0.4-numerical-aperture objective, fully
equipped for multicolor capture, and an Orca ER camera (Hamamatsu
Photonics, Bridgewater, NJ). The system was controlled by Attovision
collection software (Becton, Dickinson and Company, Franklin Lakes,
NJ), with automated infrared and image autofocus capture for 15 fields
per well for a 96-well plate. Multiple plate capture was enabled by a
Twister II robotic arm (Caliper Lifesciences Inc., Hopkinton, MA), which
was integrated with the Attovision software.
Image analysis using CellProfiler and CellProfiler Analyst. Images
acquired by automated microscopy were loaded into the open-source
software program CellProfiler (Broad Institute, Cambridge, MA), fol-
lowed by segmentation of images and identification of objects. The pro-
cess had four main steps: segmentation of nuclei, identification of whole
cells, segmentation of chlamydial inclusions, and tabulation of measure-
ments (see Fig. S1 in the supplemental material). The first task, performed
by CellProfiler, was identification of the objects. Using CellProfiler mod-
ules, the nuclei, referred to as primary objects within CellProfiler, were
identified first from the DNA-stained images. Once the nuclei had been
identified, the subsequent module used the whole-cell-stained images and
previously identified nuclei to identify the cell boundaries (whole cell),
which were referred to as secondary objects. The area of the identified
nuclei was subtracted from the whole cells to identify the cytoplasm, re-
ferred to as tertiary objects. For identification of chlamydial inclusions,
CellProfiler expanded each area of nuclei by 15 pixels and used this ex-
panded region to search for inclusions. Inclusions were then identified
and segmented. The second task performed by CellProfiler was generating
a cytological profile of each cell. CellProfiler measured a large number of
cellular and subcellular features once all objects (nuclei, cells, cytoplasm,
and identified chlamydial inclusions) had been identified. These quanti-
tative measurements consist of apparent cellular and subcellular features,
as well as an extensive amount of less-evident details, such as intensity of
the stain, size, shape, and pixel correlation between objects. Once these
measurements were taken, the cytological profile was created for each cell
to be utilized by CellProfiler Analyst (Broad Institute, Cambridge, MA)
and exported to a spreadsheet. Both nuclei and chlamydial inclusions
were related to the identified cells so that each inclusion was assigned to
only one nucleus. For enumeration of inclusion-forming units (IFU), the
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last module within the pipeline (ExportToDatabase) was modified to al-
low for classification of individual inclusion rather than cells by CellPro-
filer. To enumerate infected cells, the cytological profiles were loaded into
CellProfiler Analyst. Random images, each containing a single cell, were
presented to initiate the training process. Approximately 20 images from
the positive (infected) and negative (uninfected) controls were manually
classified by dragging and dropping the images into the appropriate bins
within the CellProfiler Analyst interface (see Fig. S2a in the supplemental
material). Based on the cytological profiles of these classified cells, Cell-
Profiler Analyst identified the parameters necessary to accurately distin-
guish between uninfected and infected cells by generating a set of 50 rules
(i.e., parameters). The software then presented a new set of cells that had
been classified as positive or negative based on the rules generated. Any
cells classified inaccurately were manually sorted into the appropriate bin
to continue the training process. To assess the accuracy of the training,
images from selected wells were opened and individual cells were auto-
matically marked as uninfected or infected by CellProfiler Analyst based
on the established rules (see Fig. S2b in the supplemental material). Any
cell that had been classified incorrectly was manually reassigned to the
appropriate bin. After the correction, a set of refined rules was generated
and used to score every cell in every image. These steps were repeated until
the system was able to accurately classify greater than 95% of cells into the
correct category. Upon completion of scoring, a spreadsheet containing
the numbers of positive and negative cells for each well was generated and
exported.
RESULTS
Evaluation of iBAChIE in a 96-well format and comparison to
manual enumeration. To evaluate the suitability of iBAChIE for
large-scale application, image acquisition and quantification of
Chlamydia infection were performed in a 96-well-plate format.
High sensitivity, reproducibility, and precision of the method
were demonstrated by quantification of infection levels among
host cells infected with 2-fold serial dilutions of C. trachomatis EBs
(see Fig. S3 in the supplemental material). In order to assess the
accuracy and efficiency of iBAChIE relative to the conventional
manual inspection, manual enumeration was performed on three
fields randomly selected from the immunofluorescence images
acquired for the automated method (see Table S1 in the supple-
mental material). Comparison of the number of host cells and
inclusion-positive cells, as well as the infection level reported by
each method, indicated that the automated method is capable of
performing highly reproducible analysis among a large set of sam-
ples with high sensitivity (a dynamic range of infections) and pre-
cision (low standard deviations).
Validation of iBAChIE with known chemical inhibitors. The
ability of iBAChIE to accurately assess the inhibitory activities of
compounds against Chlamydia infection was demonstrated using
three previously known antichlamydial compounds that inhibit
different stages of the developmental cycle: tetracycline, hydroxy-
ethyl cellulose (HEC), and polymyxin B (PMB). Tetracycline is a
broad-spectrum antibiotic, for which Chlamydia is known to be
exceptionally sensitive. Tetracycline interferes with the metabolic
process of Chlamydia by targeting translational machinery and
inhibiting protein biosynthesis (4). Complete inhibition of inclu-
sion formation by tetracycline at a concentration of 0.51 g/ml
has been previously reported (26). Infection of L929 cells with C.
trachomatis EBs along with compound treatment was performed
in a 96-well plate and analyzed 24 hpi following automated image
acquisition. iBAChIE revealed the antichlamydial effect of tetra-
cycline in a dose-dependent manner with complete inhibition of
inclusion formation at 0.5 g/ml, an inhibitory concentration
consistent with the previous report (26) (Fig. 1a).
HEC is a common polysaccharide excipient used in vaginally
delivered microbicides for STIs. Although excipients are typically
used as delivery vehicles and are expected to be pharmacologically
inactive, a 90-kDa HEC has been shown to have an inhibitory
effect on C. trachomatis infection, purportedly as a competitive
inhibitor for adhesion (20). When EBs were treated with HEC, the
inhibitory effect of HEC was directly proportional to its concen-
tration in the range of 0.175% to 0.7% and reached complete
inhibition at 1.4% (Fig. 1B). This proportionality between the
concentration and the inhibitory effect supports a previously sug-
gested mechanism for HEC inhibition, that HEC may act as a
competitive inhibitor by competing with the host cell for the rec-
ognition site on the chlamydial surface (20).
PMB is an antibiotic that typically acts by disrupting the outer
membrane of Gram-negative bacteria through interaction with
the lipid A portion of lipopolysaccharide (17, 27). PMB is active
against nearly all species of Gram-negative bacteria, including C.
trachomatis, and has been used as a positive inhibition control for
antichlamydial activity in numerous studies (11, 12, 23). In con-
trast to HEC treatment, when EBs were treated with PMB, the
concentration of the inhibitor did not show a proportional effect
on inclusion formation, suggesting a mode of inhibition different
from that of HEC. In addition, complete inhibition of inclusion
formation was not achieved even at the highest concentration of
FIG 1 Inhibitory properties of known inhibitors for C. trachomatis serovar L2 infection. Inhibitory activities of three known antichlamydial compounds,
tetracycline, 90-kDa HEC, or PMB, were determined using iBAChIE. Percent inhibition was calculated relative to the wells without treatment at 24 hpi. (a)
Tetracycline treatment. L929 cells were infected with C. trachomatis, and 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, or 0.7 g/ml of tetracycline was added along with growth
medium. Error bars indicate standard deviations of the means for triplicate wells. (b) Ninety-kilodalton-HEC treatment. L929 cells were infected with C.
trachomatis preincubated with decreasing concentrations of 5.6 to 0.175% of HEC for an hour prior to infection. Error bars represent the standard deviations of
the means for triplicate wells. (c) PMB treatment. L929 cells were infected with C. trachomatis preincubated with decreasing concentrations of 1,000 to 15.625 M
PMB for an hour prior to infection. Error bars represent the standard deviations of the means for triplicate wells.
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PMB, reaching maximum inhibition of approximately 70% at 500
M. Interestingly, previous studies show dose-dependent anti-
chlamydial activity by PMB that plateaued without reaching com-
plete inhibition (7, 16).
Efficacy of iBAChIE for measuring neutralizing antibodies.
Given the current lack of an effective vaccine against Chlamydia,
identifying and evaluating neutralizing antibodies would be ex-
tremely advantageous. iBAChIE was used to examine inhibitory
properties of polyclonal sera for chlamydial EBs. Affinity-purified
polyclonal antibody against C. trachomatis RpoA (bacterial cyto-
sol RNA polymerase  subunit) was used as a negative control.
L929 cell monolayers were inoculated with C. trachomatis EBs that
had been preincubated with anti-Chlamydia EB sera or affinity-
purified polyclonal anti-RpoA antibody, and infection levels were
analyzed 24 hpi. At the highest dose (1:100 dilution), anti-Chla-
mydia sera inhibited chlamydial infection by 98.7% relative to the
infection level of the control wells, where EBs were not pretreated
with antibody (Fig. 2). Anti-RpoA antibody treatment showed
insignificant neutralization activity, demonstrating that the neu-
tralization activity of anti-Chlamydia sera was not due to a non-
specific reaction. When the amount of anti-Chlamydia sera used
was reduced by 5-fold (1:500 dilution), the inhibitory effect was
reduced to 44.1%. No inhibitory effect was observed at the lowest
concentration (1:2,500). Together, these results indicate that this
automated method may be used to accurately identify neutraliz-
ing antibody and protective concentrations for Chlamydia infec-
tion in cell culture.
Assessment of iBAChIE with C. trachomatis (serovar D) and
the mouse Chlamydia species C. muridarum. Due to the relative
ease of cultivation and shorter developmental cycle, LGV serovar
L2 is a commonly used C. trachomatis prototype strain in chla-
mydial research. However, trachoma serovars D, E, and F are the
most prevalent urogenital strains of C. trachomatis worldwide and
therefore of more clinical relevance (18). C. muridarum is a natu-
ral pathogen of mice and is commonly used as a model for infec-
tion of the human genital tract caused by C. trachomatis.
HeLa 229 cells or L929 cells were infected with 4-fold serial
dilutions of serovar D or C. muridarum, respectively. HeLa 229
cells were used to demonstrate that various eukaryotic cells may be
used as host cell lines for the automated enumeration. Due to the
longer developmental cycle of serovar D than of L2, serovar D
infections were quantified 48 hpi and C. muridarum was quanti-
fied 24 hpi. iBAChIE measured the infection level, ranging from
81.9% to 14.0% for serovar D and 95.7% to 4.8% for C. muri-
darum in a dose-dependent manner (Fig. 3). These results support
that accurate enumeration of chlamydial infection by the auto-
mated method is highly adaptable to a wide range of serovars and
species of Chlamydia despite the differences in the duration of
developmental cycle, and eukaryotic host cell lines.
DISCUSSION
When the two methods were contrasted, a major advantage
iBAChIE exhibited over manual enumeration was the ability to
rapidly analyze large data sets. Analysis of a 96-well plate by the
automated method, accommodating enumeration of 1,440 im-
ages consisting of approximately 130,000 cells on average per
plate, was completed within 2 h following automated image ac-
quisition. During these 2 h, the average hands-on time was less
than 30 min, with the rest spent on computer processing. Notably,
analysis of multiple 96-well plates did not require additional time
compared to a single plate analysis. This is due to the fact that
regardless of the number of samples, only one training session is
required to establish a differential rule set that can be applied
across the entire experiment. Considering that manual enumera-
tion required up to 2 min per field of view, equivalent analysis
would take up to 48 h by the manual method. Thus, the automated
method achieved substantial time savings in sample analysis.
iBAChIE is equally effective in analysis of small-scale (up to
hundreds of images) or large-scale screens containing thousands
of images. While analysis of hundreds of images by CellProfiler
can be completed on a single computer in a few hours, the exper-
iments described in this study consisted of thousands of images,
and therefore more computational processing capabilities were
needed to achieve rapid analysis (25). This challenge was ad-
dressed by utilizing a dedicated “cluster” of processors (16 quad-
core 2.5 GHz processors) for image processing. With addition of
an extra module to the end of a pipeline, CellProfiler automati-
cally divided images into small batches and created the files con-
taining batches of images, which were then submitted as individ-
ual jobs to be processed separately by the cluster, significantly
minimizing the time required for data processing (1).
In summary, an automated method (iBAChIE) utilizing Cell-
Profiler and CellProfiler Analyst has been developed and validated
FIG 2 Inhibitory properties of anti-Chlamydia sera for infectivity of C. tra-
chomatis L2 EBs. The ability of anti-Chlamydia sera to neutralize the infectivity
of C. trachomatis L2 EBs was evaluated using iBAChIE. L929 cells were infected
with C. trachomatis EBs preincubated with various concentrations of anti-
RpoA antibody or anti-Chlamydia sera for 30 min prior to infection. Percent
inhibition was calculated relative to the wells without treatment following 24 h
of incubation. ND, no inhibition was detected.
FIG 3 Automated enumeration of C. trachomatis serovar D and C. muri-
darum infection. Percent infectivity for a 4-fold dilution series of C. trachoma-
tis serovar D (a) or C. muridarum (b) was determined by the automated
method. Infections were carried out in triplicate wells for each dilution. Per-
cent infectivity was calculated based on the numbers of infected and unin-
fected cells identified by CellProfiler Analyst. Error bars indicate standard
deviations of the means for triplicate wells.
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for rapid and accurate analysis of Chlamydia infection. The ability
of iBAChIE for evaluation of various inhibitory molecules, along
with simultaneous and rapid analysis of large-scale experiments
(i.e., multiple 96-well plates), supports that this method could
readily be applied to high-throughput screening of small-mole-
cule libraries for antichlamydial agent and vaccine development.
In addition to the potential screening capabilities, iBAChIE offers
a high-throughput tool for a wide variety of chlamydial research
that currently relies on manual analysis of fluorescence micros-
copy images by using fluorescently labeled chlamydial proteins or
host subcellular markers. The combined use of CellProfiler and
CellProfiler Analyst may find applications in the research of mi-
croorganisms where no well-established high-throughput quanti-
fication is currently available and offer a powerful tool in a wide
range of studies, including drug discovery.
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